Niki BioSolutions,

Niki BioSolutions, FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Niki BioSolutions, (NIKI) as of Oct 16, 2026 is 134.72 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 27.88 % — a change of 383.28% (higher).

FCF Conversion

134.72 %

YoY

383.28%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Niki BioSolutions, is 2025 134.72 % . FCF Conversion Rate (FCF/EBITDA) of Niki BioSolutions, was 2024 27.88 % . It decreases by 383.28% higher compared to the previous year.

The Niki BioSolutions, FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
108.55 USD
Jan 1, 2019
77.54 USD
Jan 1, 2020
-227.72 USD
Jan 1, 2021
59.04 USD
Jan 1, 2022
127.61 USD
Jan 1, 2023
273.54 USD
Jan 1, 2024
27.88 USD
Jan 1, 2025
134.72 USD
The Niki BioSolutions, FCF Conversion history
YEARFCF ConversionYoY
134.72 %+383.28%
27.88 %-89.81%
273.54 %+114.35%
127.61 %+116.13%
59.04 %-125.93%
-227.72 %-393.69%
77.54 %-28.57%
108.55 %-68.73%
347.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Niki BioSolutions, Stock analysis

What does Niki BioSolutions, do? Niki BioSolutions, Inc. is a clinical-stage biopharmaceutical company based in Princeton, US, focused on developing therapeutic products for oncology and infectious diseases. The company operates through a pipeline including SACT-1 (Phase 1 for neuroblastoma), ALS-4 (Phase 1 for bacterial infections), and preclinical candidates like SACT-COV19 and ALS-1 targeting coronavirus and MRSA. It was formerly Aptorum Group Limited, rebranding in July 2026 following its listing on 17 July 2026. Niki BioSolutions, is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Niki BioSolutions, stock

FCF Conversion Rate (FCF/EBITDA) of Niki BioSolutions, is 134.72 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Niki BioSolutions, changed from 27.88 % to 134.72 %, representing a 383.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Niki BioSolutions, since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Niki BioSolutions, with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Niki BioSolutions,

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Niki BioSolutions,